metformin has been researched along with Ataxia Telangiectasia Syndrome in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P | 1 |
| Cao, Y | 1 |
| Guo, Y | 1 |
| Xu, Q | 1 |
| Wang, X | 1 |
| Zhang, L | 1 |
| Liu, Z | 1 |
| Chen, D | 1 |
| Chen, S | 2 |
1 other study available for metformin and Ataxia Telangiectasia Syndrome
| Article | Year |
|---|---|
Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Blood Glucose; Diabetes Mellitus, Typ | 2022 |